Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Mar 8;2:7. doi: 10.1186/s40780-016-0042-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Kaneko et al. 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 1 — Scatter plots with fits correlating methotrexate results (μmol/L) obtained by the reference method TBA-25FR with results obtained by TD_X/FL_X immunoassay at total samples (a), 24 h (b), 48 h (c), and 72 h (d) after the start of treatment. Assay results were very consistent between the two immunoassay systems, with good correlation total samples after the start of treatment (TBA-25FR = 1.05*TD_X/FL_X, −0.29, r = 0.99; Fig. 1a), 24 h after the start of treatment (TBA-25FR = 1.06*TD_X/FL_X, −1.31, r = 0.99; Fig. 1b), 48 h after the start of treatment (TBA-25FR = 1.00*TD_X/FL_X, +0.027, r > 0.99; Fig. 1c), and 72 h after the start of treatment (TBA-25FR = 1.09*TD_X/FL_X, +0.011, r > 0.99; Fig. 1d)